The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesBL: Use at an assay dependent dilution. Dilutions should be made according to the amount of CNF1 to be inactivated.
Dot (native conditions): Use at an assay dependent dilution.
WB: Use at an assay dependent dilution. Starting dilution 1/10. Predicted molecular weight: 115 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
RelevanceCNF1 and CNF2 belong to a family of bacterial toxins that target the small GTP-binding Rho proteins that regulate the actin cytoskeleton. Members of this toxin family typically inactivate Rho; however, CNF1 and the highly related CNF2, activate Rho by deamidation. CNF1 is more frequently associated with E.coli strains that cause extraintestinal infections in humans, particularly those of the urinary tract. In CNF1-producing uropathogenic E.coli strains, CNF1 is chromosomally encoded and typically resides on a pathogenic island that also contains hemolysin and P fimbria-related genes. Both CNF1 and the highly related CNF2 are monomeric, cytoplasmic toxins of approximately 115 kDa. CNF1 can be structurally organised into 3 functional domains : the N-terminal, central and C-terminal domains. The latter exhibits the catalytic activity of the toxin.
References for Anti-CNF1 antibody [NG8] (ab37253)
has not yet been referenced specifically in any publications.
Publishing research using ab37253? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"